Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30231 | 1.00 | CYP3A4 (0.54) | CYP3A4ALDH1A1MAPK1SMN1; SMN2GAA | |
| SCHEMBL121851 | 0.87 | TSHR (0.46) | ALDH1A1SMN1; SMN2GAAMAPTMEN1 | |
| SCHEMBL5710118 | 0.87 | CYP3A4 (0.54) | CYP3A4ALDH1A1MAPK1SMN1; SMN2GAA | |
| SCHEMBL29789730 | 0.83 | NPC1 (0.45) | ALDH1A1SMN1; SMN2GAAMAPTNPC1 | |
| SCHEMBL8475 | 0.83 | NPC1 (0.45) | ALDH1A1SMN1; SMN2GAAMAPTNPC1 | |
| SCHEMBL21273121 | 0.83 | ENPP2 (0.37) | CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL10269417 | 0.80 | ALDH1A1 (0.63) | CYP3A4ALDH1A1MAPK1SMN1; SMN2GAA | |
| SCHEMBL28751379 | 0.79 | CYP3A4 (0.46) | CYP3A4ALDH1A1MAPK1SMN1; SMN2GAA | |
| SCHEMBL7710496 | 0.79 | CYP3A4 (0.46) | CYP3A4ALDH1A1MAPK1SMN1; SMN2GAA | |
| SCHEMBL17236458 | 0.78 | CYP3A4 (0.48) | CYP3A4ALDH1A1MAPK1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036736-A | Pyrrolo [2,3-d ] pyrimidine derivative, synthetic method and application | 云南大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122029157-A | Bilobalide derivatives for the treatment of neurological diseases and cancers | 香港中文大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-115232090-B | 6-Substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2, 2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2024-11-19 | — | — | CN | disclosed |
| CN-118894816-A | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-11-05 | — | — | CN | disclosed |
| EP-4436968-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-113330001-B | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-07-02 | — | — | CN | disclosed |
| CN-114507181-B | Propionic acid compound containing 5-substituted tetrahydroisoquinoline, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-03-26 | — | — | CN | disclosed |
| CN-111868055-B | Inhibitors of TRPC6 | 勃林格殷格翰国际有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-115181050-B | Preparation method and application of 2-phenylindole derivative | 石河子大学 | 2024-01-30 | — | — | CN | disclosed |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| CN-116253687-A | Diaryl pyrimidine compound and preparation method and application thereof | 复旦大学 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023081441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | CD22, CD2, CD2BP2 | CYP3A4 775/4885ALDH1A1 778/4885MAPK1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.